"In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable."
Given that Neuren, post FDA approval, is now trading at a price around the same as after successful phase 2 results, why would a buyer pay a 300% premium?
Ann: 2023 Annual Report to shareholders, page-143
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $30.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.68 | 45 | 1 |
View Market Depth
| Last trade - 16.16pm 24/05/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable